Previous 10 | Next 10 |
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private inve...
-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CEPI show good tolerability and immunogenicity in all vaccine-naïve subjects...
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims t...
Summary Gritstone bio results from the phase 1/2 study, using SLATE vaccines in treating patients with KRAS mutant MSS-CRC and NSCLC, were positive with a 39% molecular response observed. Molecular response achieved in KRAS mutant NSCLC patients led to a doubling of overall surviv...
The following slide deck was published by Gritstone bio, Inc. in conjunction with this event. For further details see: Gritstone bio (GRTS) Presents at ESMO Congress 2022
Why The Stock Market Is Down Today The stock market is down today because of the latest round of August CPI data . The numbers came in higher than expected and what many hoped to be another month showing inflation was slowing became the stark reality that Fed Chairman Jerome Powell&...
Gritstone bio ( NASDAQ: GRTS ) said its SLATE vaccines (version 1 and SLATE-KRAS) showed early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC...
-- SLATE vaccines (version 1 and SLATE-KRAS) demonstrate early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) -- -- Molecular response, as measu...
EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking ...
Gritstone bio ( NASDAQ: GRTS ) slipped ~14% in the pre-market trading Monday after Goldman Sachs downgraded the immunotherapy developer to Sell from Neutral, citing concerns over its liquidity position. The analyst Corinne Jenkins thinks that GRTS' current cash positio...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...